Pharma-Bio Serv earnings up in April 2026 quarter
Pharma-Bio Serv, Inc. reported higher revenue and profit for the quarter ended April 30, 2026.
Rhea-AI Filing Summary
Pharma-Bio Serv, Inc. reported higher revenue and profit for the quarter ended April 30, 2026. Revenue for the three and six months was approximately $2.7 million and $5.0 million, up about $0.3 million and $0.1 million from the same periods last year.
Net income for the three and six months reached approximately $0.2 million and $0.3 million, increases of about $0.1 million and $0.2 million year over year. Management highlighted stronger profitability driven by focusing on higher-opportunity markets and maintaining disciplined cost control and operational efficiency.
Positive
- None.
Negative
- None.
Key Figures
Quarterly revenue: $2.7 million
Six-month revenue: $5.0 million
Quarterly net income: $0.2 million
+1 more
4 metrics
Quarterly revenue
$2.7 million
Three months ended April 30, 2026; up about $0.3M YoY
Six-month revenue
$5.0 million
Six months ended April 30, 2026; up about $0.1M YoY
Quarterly net income
$0.2 million
Three months ended April 30, 2026; up about $0.1M YoY
Six-month net income
$0.3 million
Six months ended April 30, 2026; up about $0.2M YoY
Key Terms
regulatory compliance consulting, technology transfer support, forward-looking statements, Risk Factors, +1 more
5 terms
regulatory compliance consulting financial
"Pharma-Bio Serv’s core business is FDA and international agencies regulatory compliance consulting related services."
technology transfer support financial
"a compliance, project management and technology transfer support consulting firm today announced that revenues..."
forward-looking statements regulatory
"This news release contains “forward-looking statements” within the meaning of the U.S. federal securities laws..."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Risk Factors regulatory
"Important factors that could cause Pharma-Bio Serv’s actual results... include those set forth in the “Risk Factors” section..."
Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.
Annual Report on Form 10-K regulatory
"include those set forth in the “Risk Factors” section of Pharma-Bio Serv’s Annual Report on Form 10-K..."
An annual report on Form 10‑K is a required, comprehensive filing that publicly traded companies give to regulators and investors summarizing their business, results of operations, detailed financial statements reviewed by independent auditors, material risks, legal issues and management’s discussion of performance. Investors use it like a company’s year‑end report card and medical checkup: it reveals how the business made money, where it is vulnerable, and the facts needed to compare value, judge risk and make informed investment decisions.
Earnings Snapshot
Revenue (three months): $2.7 million
quarter ended April 30, 2026
Revenue (three months)
$2.7 million
+$0.3 million vs prior-year quarter
Revenue (six months)
$5.0 million
+$0.1 million vs prior-year period
Net income (three months)
$0.2 million
+$0.1 million vs prior-year quarter
Net income (six months)
$0.3 million
+$0.2 million vs prior-year period
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Pharma-Bio Serv (PBSV) perform in the quarter ended April 30, 2026?
Pharma-Bio Serv delivered higher revenue and profit in the quarter ended April 30, 2026, with improved profitability. Management cited strategic market focus and disciplined cost control as key drivers of the better financial performance compared to the same period last year.
What were Pharma-Bio Serv (PBSV) revenues for the three and six months ended April 30, 2026?
Pharma-Bio Serv reported revenue of approximately $2.7 million for three months and $5.0 million for six months ended April 30, 2026. These figures represent increases of about $0.3 million and $0.1 million versus the comparable periods a year earlier.
What net income did Pharma-Bio Serv (PBSV) report for the quarter and year-to-date 2026?
Net income was approximately $0.2 million for the three months and $0.3 million for the six months ended April 30, 2026. These results were about $0.1 million and $0.2 million higher than the same periods in the prior year, reflecting stronger profitability.
What factors contributed to Pharma-Bio Serv (PBSV) improving profitability?
Management stated that improved profitability resulted from focusing on markets offering the greatest return opportunities and maintaining disciplined cost management and operational efficiency. This combination supported better financial performance for the quarter and year-to-date compared with last year.
What services and markets does Pharma-Bio Serv (PBSV) focus on?
Pharma-Bio Serv provides regulatory compliance consulting, project management, and technology transfer support services. It serves pharmaceutical, biotechnology, medical device, cosmetic, food, and related industries across Puerto Rico, the United States, Europe, and Brazil through a global team of specialized professionals.
Does the Pharma-Bio Serv (PBSV) update include forward-looking statements?
Yes, the update includes forward-looking statements based on management’s expectations as of the announcement date. The company notes these statements involve significant business and economic risks and refers investors to its Form 10-K risk factors filed with the SEC for additional details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
